Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases

• DOI: 10.1038/cddis.2013.219
• Publication Date: 2013-06-27T14:39:51Z
• Authors: M Barathan; V Mariappan; E M Shankar; B JJ Abdullah; K L Goh; J Vadivelu
• Keywords: Hypericin

Abstract Photodynamic therapy (PDT) has emerged as a capable therapeutic modality for the treatment of cancer. PDT is targeted cancer that reportedly leads to tumor cell apoptosis and/or necrosis by facilitating secretion certain pro-inflammatory cytokines and expression multiple apoptotic mediators in microenvironment. In addition, also triggers oxidative stress directs killing activation inflammatory responses. However, cellular molecular mechanisms underlying role remain ambiguous. Here, we investigated ability association with hypericin (HY) induce induction reactive oxygen species (ROS) Th1/Th2/Th17 human hepatocellular liver carcinoma line (HepG2) cells. To discover if any were implicated enhancement death HY-PDT-treated cells, selected gene profiling response HY-PDT was implemented. Experimental results showed interleukin (IL)-6 significantly increased all especially 1 μ g/ml HY-PDT, resulting death. quantitative real-time PCR analysis revealed genes, such BH3-interacting-domain agonist ( BID ), cytochrome complex CYT-C ) caspases CASP3, 6, 7, 8 9 remarkably higher HepG2 cells than untreated entailing destruction immune-mediated occurs only PDT-treated Hence, induces cytotoxic ROS, potentially recruits IL-6 mediators, providing additional hints existence alternative anti-tumor immunity carcinoma, which contribute long-term suppression growth following PDT.